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[57] ABSTRACT
Continuous hybrid cell lines for producing monoclonal
antibodies directed against antigens of Treponema palli-
dum have been developed. The hybrid cell lines were
established by fusing differentiated lymphoid cells
primed with antigens of Treponema pallidum with hy-
bridoma cells. The resulting fused cells were cloned,
isolated, cultured and characterized as to antibody spec-
ificity against antigenic determinants of Treponema pal-
lidum. :
9 Claims, No Drawings
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HYBRID CELL LINES PRODUCING
MONOCLONAL ANTIBODIES DIRECTED
AGAINST TREPONEMA
The Government hasrights in the invention pursuantto National Institutes of Health Grant Nos. AI-16692,AI-11851 and CA-23115 awarded by the Department of
Health and Human Services.
BACKGROUNDOF THE INVENTION
The present invention relates to the production ofmonoclonalantibodies; and, in particular, to hybrid celllines capable of continuously producing monoclonalantibodies directed against Treponemabacterial patho-gens.
In recent years, the capability to produce monoclonalantibodies specific for the immunogenic determinants ofbacterial cells and toxins has provided a new vista ofdiagnostic and immunotherapeutic agents.
The bacterial genus Treponemais associated with avariety of pathogenic diseases. Of particular signifi-cance, Treponema pallidum is a sexually transmitted
bacterial pathogen of man responsibe for syphilis. Very
little is known about T. pallidum, despite decades of
strenuousefforts to understand this organism. The gross
lack of information stems primarily from the fact that T.
pallidum is one of the very few bacterial pathogensfor
man that cannot be grownin vitro like other human
pathogens. Consequently, researchers attempting to
elucidate the nature of the organism and the diseaseit
produces have been confined to cultivating T. pallidum
in the testicles of laboratory rabbits.Untreated syphilis in man is a severe, chronic, andvery complex disease that can often be extremely diffi-cult to diagnose. Limitations with current diagnostictools and the absence of a vaccine have allowedsyphilisto flourish at the estimated frequency of approximately350,000 cases per year in the United States alone, evenwith the availability of effective penicillin treatment.Moreover, there are other treponemal diseases whichperhaps have a more worldwide impact with respect tomorbidity and mortality. Briefly, the treponemes thatcause yaws,pinta, and bejel are treponemes morpholog-ically and serologically indistinguishable from T. palli-
dum. These diseases are very serious worldwide, espe-
cially in the socalled third world countries. These dis-eases are believed to be transmitted through normal
person-to-person contact, as opposed to T. pallidum,which is a sexually transmitted agent. As a result theseparticular diseases are highly contagious and devastat-ing to large populations thereby eludingeffective con-trol.
Many attempts at vaccine development over past
decades using whole cells, extracts, or adjuvant prepa-rations of T. pallidum or other non-pathogenic trepo-nemes have failed. One study reported the successful
vaccination of rabbits with T. pallidum (Nichols) atten-
uated by y-irradiation. There are several major draw-
backs to this approach as a potential immunization
scheme for humans. These include the impracticality of
preparing massive amounts of freshly isolated andfreshly irradiated treponemes, as well as the dangers
associated with hypersensitivity reactions by the recipi-
ent to contaminating rabbit proteins present in trepone-mal suspensions.
Syphilis and other related pathogenic treponemal
disease research continuesto lag far behind other areas
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of bacterial infectious disease. In particular, the com-plexity of the humoral response to T: pallidum infectionandtheinability to obtain large amountsof T: pallidumcells for subsequent fractionation of constituent anti-gens have severely hamperedidentification of the spe-cific immunogensof T. pallidum that are responsible foreliciting protective immunity in rabbits and man. Thespecific T. pallidum immunogens that remain unidenti-fied and uncharacterized may hold the key to immuno-logical approaches for the control of syphilis.
The somatic cell fusion of plasmacytoma cell lineswith treponemal-sensitized spleen or lymph node cellsto produce monoclonalantibodies specific for a trepo-nemal species determinant provides a new and innova-tive way to circumvent major obstacles of the past.Once successfully carried out, a virtually limitless sup-ply of monospecific antibodies for Treponema pallidumantigens will be readily available at all times. Thesemonospecific antibodies could then be used to analyzethe antigenic components of the Treponema immuno-gens. The isolation and characterization of specificTreponema immunogens through the use of the newhybridomacell fusion technology may provide the ma-terials and insights needed to understandthe pathogene-sis and immunological control of syphilis, yaws, pinta,
and bejel through vaccine development.The invention seeks to develop continuous hybridcell lines which produce monoclonal antibody directedagainst treponemal antigens. Selected cell lines are ca-pable of continuously producing a set of monospecificantibodies that are identical with respect to combiningsite specificity to a single antigenic determinant exhib-ited by a treponemalbacteria.
SUMMARY OF THE INVENTION
In accordance with the present invention, continuoushybridomacell lines are established which elaborateand secrete higly specific and homogenous monoclonalantibodies to treponemal antigens, in particular Trepo-
nemapallidum.
In its broadest aspect, the invention involves firstimmunizing an animal to Treponema bacteria to de-velop lymphocytes and their differentiated progenywhich produce antibodies directed against a primingantigenic determinant. The lymphocytes are recovered
and fused with myeloma, plasmacytoma, or hybridoma
cells to form somatic cell hybrids. The cell hybrids are
cultured, selected, isolated and propagated in tissueculture. Thereafter, the hybrid cell lines are capable ofindefinitely producing monoclonal antibodies to theselected immunizing antigens.
In accordance with the present invention there areprovided continuous hybrid cell lines that producemonoclonal antibody against antigenic determinats ofTreponema. Continuous cell lines have been isolatedwhich produce monoclonal antibody directed specifi-cally against T: pallidum antigens or against treponemalgroup antigens (antibody which cross react among sev-eral of the Treponema species). Moreover, there areprovided complement fixing monoclonal antibodieswhich are capable of immobilizing virulent treponemes.
DETAILED DESCRIPTION OF PREFERREDEMBODIMENTS
The following discussion is in terms of the preferredembodimentsof this invention, which representthe bestmode knownto the Applicants at the timeofthis appli-cation.
4,514,498 .3
In accordance with the processes of this invention,
test animals are stimulated in vivo for antibody produc-
tion by immunization with a preparation containing
Treponema bacteria. Applicants have directed their
preferred embodiment to immunizing mice with a T.
pallidum inoculum extracted from rabbit testicles.
Alternatively, normal and immune differentiated
lymphocytes capable of producing antibody can be
isolated from test animals, cultured, and primed with
Treponema in vitro to generate cells appropriate for
producing lymphocyte hybridomas. For example, such
methods of in vitro stimulation with mitogens and/or
antigens have been described by Robertsonet al, Micro-
biology 1980 pp. 181-185 (1980) and Kettmanet al, J.
Immunol. Methods 39:203-222 (1980) or the method
splenic fragment culture as described by Press et al,
Eur. J. Immunol. 4:155-159 (1974).
The route and schedule of immunizing the host ani-
mal or cultured antibody producing cells therefrom are
generally in keeping with established and conventional
techniques for antibody stimulation and production.
Applicants have employed mice as the test model al-
though it is contemplated that any mammalian subject
including human subjects or antibody producing cells
therefrom can be manipulated according to the pro-
cesses of this invention to serve as the basis for produc-
tion of human hybrid cell lines.
After immunization, immune lymphoid cells are fused
with myeloma, plasmacytoma, or hybridoma cells
(hereinafter referred to collectively as myelomacells)
to generate a hybrid cell line which can be cultivated
and subcultivated indefinitely, to produce large quanti-
ties of monoclonal antibodies. For purposes ofthis in-
vention, the immune lymphoid cells selected for fusion
are lymphocytes and their normal differentiated prog-
eny, taken either from lymph nodetissue or spleentis-
sue from immunized animals. Applicants prefer to em-
ploy immunespleen cells, since they offer a more con-
centrated and convenient source of antibody producing
cells with respect to the mouse system.
The myeloma cells provide the basis for continuous
propagation of the fused hybrid. Myelomacells are
tumorcells derived from plasma cells which show pref-
erence for bone marrow. Plasmacytomacells are neo-
plastic cells derived from plasmacells. In particular,
Applicants prefer to use lymphocyte hybridoma cells
which secrete no immunoglobulin. Lymphocyte hy-
bridomacells are cells generated by the fusion of my-
elomaor plasmacytomacells with normaldifferentiated
lymphoid cells. Myeloma, plasmacytoma, and hy-
bridomascan be selected to be devoid of immunoglobu-
lin synthesis.
Theparticular species of animal from which the my-
eloma and immunized antibody producing cells are
derived are notcritical, in that it is possible to fuse cells
of one species with another. However, it is preferred
that the source of immunized antibody producingcells
and myeloma be from the samespecies.
Generally the fusion techniques employed are ac-
cording to the procedures set out by Kohleret al, Eur.
J. Immunol. 6:11-19 (1976) and Kennett et al, Lympho-
cyte Hybridomas—Current Topics in Microbiology and
Immunology 81: 77-91 (1978) Springer-Verlag, New
York. Fusion is generally accomplished by adding a
suspension of antibody producingcells to the myeloma
cells in growth medium and thereafter centrifuging to
form apellet.
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The fused hybrids are next screened for antibody
production specific for treponemal antigens. A hy-
bridoma which secretes antibody specific for a trepone-
mal antigenic determinant is selected and cultured to
establish a continuouscell line with stable genetic cod-
ing. The cell line can be stored and preserved in any of
a numberof conventional ways, including freezing and
storage underliquid nitrogen. A frozen cell line can be
revived and cultured indefinitely with resumed synthe-
sis and secretion of monoclonal antibodies specific for
the selectedantigenic determinant. The secreted anti-
body is recovered from tissue culture supernatant by
conventional precipitation, ton exchange,affinity chro-
matography,or the like. The recovered antibody can be
freeze dried and stored underrefrigeration for at least
several weeks withoutsignificant loss of activity.
The following examples are offered to illustrate a
particular embodimentofthe invention but they are not
intended to limit it.
A. Preparation of Antigens
T. pallidum (Nichols) was used for sensitizing mice
and as a source of antigen in the radioimmunoassay
(RIA). The organisms were cultivated in thetesticles of
New Zealand White rabbits, previously examined upon
receipt for the absence of clinical and serological
(VDRLnon-reactive) evidence of Treponema paraluis-
cuniculi infection; the animals were subsequently
housed individually at 18°-20° C. with antibiotic-free
food and water given ad libitum. Approximately 12
days following each intratesticular injection of 2x 107
T. pallidum in one miofserum-saline extraction medium
[0.01M sodium phosphate buffer, pH 7.2, 0.85%
(wt/vol) NaCl, 50% (vol/vol) heat-inactivated (56° C.,
30 min) normal rabbit serum] per testicle, treponemes
were extracted aerobically from minced testicles by
rotary shaking at 180 rpm (23° C.) for 30 min using 10
mil of extraction medium pertesticle. Gross rabbit testic-
ular tissue debris was removed from the treponemal
suspension by centrifugation twice at 500x g for 10 min
at 23° C. in a 50 ml conical polypropylene centrifuge
tube. Treponemesin suspension were then examined for
motility, concentrated by centrifugation at 16,000xg
for 20 min, suspended in phosphate buffered saline
(PBS) (0.01M sodium phosphate buffer, 0.85% NaCl,
pH 7.2), and enumerated by darkfield microscopy.
“Fresh” treponemes were used immediately upon isola-
tion to prepare RIA plates, which could be stored at
—70° C. “Aged” treponemes were producedby storing
suspensions of 7: pallidum in PBS at 4° C. for 7 days
before binding to microtiter plate wells for RIA.
T. phagedenis biotype Reiter (Reiter treponeme) was
used in a RIA to identify antibodies directed against
Treponema groupantigens. The organisms were main-
tained at 23° C. and transferred monthly in BBL Thio-
glycollate Medium 135C (withoutindicator) containing
10% (vol/vol) heat-inactivated (56° C., 30 min.) sterile
bovine serum. Cells for use in RIA werecultivated for
5 days at 35° C. in large screw capped tubes containing
40 ml of BBL Spirolate Broth supplemented with 4 ml
of sterile bovine serum (total vol. of 44 ml per tube).
Cells from 5 tubes were collected by centrifugation,
washedtwice by centrifugation in 40 mlofsterile PBS,
and suspendedin PBSat a cell density of approximately
1X 108 cells per ml as determined by darkfield micros-
copy.
A rabbit testicular antigen extract for RIA was pre-
pared from the testicles of normal, uninfected, VDRL
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non-reactive rabbits for the detection of monoclonal
antibodies that cross-reacted with rabbit antigens or
were directed against contaminating rabbit host anti-
gens present in T. pallidum suspensions (used for the
sensitization of mice). Testicles were minced and ex-
tracted in serum-saline medium asdescribed for T. palli-
dum, but centrifuged only once for 7 min at 250X g,yielding a turbid supernatant. Ten microliters of thisrabbit antigen preparation were used per microtiter
plate well in the RIA. Protein assays indicated that 10
microliters of this preparation contained about 120 pe
of total rabbit protein and that 50% ofthis total proteinwas due to the normal rabbit serum in the serum-saline
extraction medium. Preparations stored for up to 6 ;months at —20° C. appeared to react equally as well asfreshly-prepared extracts in the RIA.
Sonicated suspensionsof T.. pallidum or T. phagedenis
biotype Reiter were also used as RIA antigen to detect
antibodies directed against either “masked”, subsurface
or cytoplasmic treponemal antigens. Treponemal sus-pensions of approximately 1108 cells per ml in PBS
were sonicated for a total of 3 min (6 min at 50% pulse)
(on ice) using a stepped microtip and a Branson Sonifier
Model W350set for an output of 4 (about 40 W). Ten plof these sonicafe suspensions were used per microtiter
plate well in the RIA. Unused suspension werestored at—20° C,
B. Plasmacytoma Cell Line
The mouse plasmacytoma cell line SP2/0-Ag14
(SP2/0), which is a hybrid cell line derived from
SP2/HGLKformed from the hybridization between aBALB/c mouse spleen cell and the myelomacell line%63/Ag8 described by Schulman et al, Nature 276:
269-270 (1978) was the cell line used in this study.
SP2/0 synthesizes no Ig heavy orlight chains,is resis-tant to 20 wg of 8-azaguanine per ml, and is killed inhypoxanthine-aminopterin-thymidine (HAT) medium.SP2/0 cells are maintainedin vitro in Dulbecco’s Modi-fied Eagle’s Medium with high glucose (DMEM)(Grand Island Biological Company, Grand Island,
N.Y.) supplemented with 15% (vol/vol) fetal calf
serum (Hy-Clone FCS;Sterile Systems, Logan, Utah), 2mM glutamine, and 50 units of penicillin/streptomycin
(GIBCO) per ml.
C. Immunization Schedule for Hybridoma Production
Adult female BALB/c mice (6-8 weeks old) werepurchased from Jackson Laboratories (Bar Harbor,Me.) and used as a source of splenic lymphocytes pro-ducing antibodies against T. pallidum antigens. Micewereinitially immunized with freshly-prepared T. palli-
dum cells in PBS (2X 108 cells/0.15 ml PBS) in com-plete Freunds adjuvant (1:1) intraperitoneally (IP).Three additional injections of 2107 freshly isolatedorganisms (0.3 ml PBS; IP) were given on days 21, 42,and 63, and a final injection of 1.2 x 107 organismsin 0.4ml PBS (0.2 ml IP and 0.2 ml intravenously) on day 84.
Three days following the last injection, spleens wereremoved aseptically from two mice and thespleencellswere prepared for hybridomacell fusion by gently teas-ing them with forceps to prepare a single cell suspensionin DMEM. The cells were then washed three timeswith DMEMbycentrifugation at 270g for 10 min at8° C.
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D. Construction of Hybridomas
Hybridomas were produced by fusing spleen cellsfrom the immunized mice with murine SP2/0-Ag14hybridomacells (SP2/0 hereinafter) using a modifica-tion of the basic procedure of Kennettetal, LymphocyteHybridomas—Current Topics in Microbiology and Immu-nology, Vol. 81, pp. 77-91 (1978) Springer-Verlag, NewYork. Suitable cell lines were obtained from RogerKennett, University of Pennsylvania Medical School asoriginally set forth by Schulmanetal, supra.Plasmacytomacells were harvested from culture inthe logarithmic phase of growth,pelleted by centrifuga-tion at 270g for 10 min, and washed three times in.DMEM.Approximately 1107 SP2/0 cells and thewashed spleen cells were mixed togetherat a ratio of 7viable spleen cells per viable SP2/0.cell and pelleted bycentrifugation. After the supernatant was removed, 0.2mi of warm (37° C.) polyethylene glycol (35% wt/volin DMEM; PEG 1000; J. T. Baker Chemical Company,Phillipsburg, N.J.) was added to the pellet to cause cellfusion.
Thecells were then pelleted, washed in DMEM,andresuspendedin 25-60 ml ofDME-Hy medium(see Ken-nett et al, supra at p. 78) at approximately 4x 106cells/ml and plated under the conditions of limitingdilution in 50 yl aliquots in 96 well microtiter plates(Costar Plastics, Vineland, N.J.). This fusion prooedurediffers from the method of Kennett et al, supra in thatthe SP2/0-spleen cell mixture, PEG, and DMEMareallkept at 37° C. for the fusion processes. Thecellpelletisloosened with a glass rod to ensure gentle mixing ofthecells and the cells remain in PEG for 3 min. at 37° C.and for approximately 5 min. at 8° C. (during centrifu-gation).
A two-fold concentration of HAT selection compo-nents in media, as specified in Littlefield et al, Science145: 709-710 (1964), was added to each well (50 pl) onday 2, followed by a 100 pl of HAT-medium on day4.Hybrids could be. observed after 6-10 days. Wellswhich contained growing cells were subdivided intoanother 96 well plate, grown, and transferred into 24well tissue culture plates (Costar Plastics) for mainte-nance. Culture supernatants were harvested for use inthe screening assays for anti-T. pallidum reactivity and
determination of monoclonalisotype.
E. Characterization of Monoclonal Antibody
RIA Screening Assays for Hybridomas SecretingMonoclonal Antibodies Against T. pallidum
To each well of a Cooke 96 well microtiter plate(Dynatech Laboratories, Alexandria, Va.) was added 10pl of a suspension or sonicate of T. pallidum or T. pha-gedenis biotype Reiter containing the equivalent of1X 108 cells per ml in PBS or the rabbit testicular ex-tract described earlier. Followingincubation at 4° C.overnight to dryness, the wells were washed 3 timeseach with 0.2 ml portions of PBS containing 0.02%sodium azide to remove non-adhering antigen. Due tothe strong affinity of treponemal and rabbit testiculartissue antigens for polyvinyl-chloride and otherplastics,it was unnecessary to employ fixatives to promote bind-ing of these antigens to the microtiter plate wells. Ifdesired, however, 20 pl of 10% ethanol in each wellfollowed by evaporation to dryness at 37° C. can beutilized for fixation. Wells were then precoated with 0.2mi of PBS+ 1% (wt/vol) bovine serum albuminat 4° C.overnight, and washed 3 times with 0.2 ml of PBS-+-a-
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zide. Plates were used the same day or one day follow-
ing preparation.
For the RIA test, 0.05 ml of a 4 day old hybridoma
clone supernatant was added to each well containing a
respective antigen preparation. After 3 hr at 23° C., the 5
wells were washed 3 times with 0.2 ml PBS-+ azide,
followed by the addition of 2.6 105 CPM of a mixture
of affinity purified !25]-labeled rabbit anti-mouse IgG
(specific activity of 2.0x 106 CPM per pg) and IgM
(specific activity of 3.7106 CPM per jg) in 0.1 ml of
PBS-+azide+2% (vol/vol) horse serum per well. Bind-
ing of this probe was carried out overnight at 4° C.
Wells were then washed extensively with PBS and tap
water. Following drying of the plates and cutting ofthe
—_
individual wells, counting of the wells was performed in 15
a Nuclear Chicago model 1185 gammacounterfor 0.4
minute.
Antisera used as positive controls in the RIA in-
cluded (1) mouse anti-7. pallidum serum collected from
mice used as a source of splenic lymphocytes in cell
fusions, and (2) mouse anti-rabbit testicular extract
serum produced by immunizing BALB/c mice with
rabbit testicular extract preparations. The mouse anti-
rabbit testicular extract serum was generated by immu-
nizing mice intraperitoneally on day 1 (0.25 ml testicu-
lar extract+0.25 ml complete Freund’s adjuvant) and
0.3 ml of extract on days 30 and 51, followed bycollec-
tion of the serum on day 72.
A total of 39 hybridomacell lines were identified by
RIA assecretors of monoclonal antibodies that reacted
with T. pallidum antigens. Reactivity in the RIA was
considered positive if !25I counts per 0.4 min were
above 600 (background counts generally were in the
order of 200-300). On this basis, the monoclonal anti-
bodies arising from anti-T. pallidum hybridomas could
be grouped into 3 major categories. One group of
monoclonal antibodies was directed specifically against
T. pallidum antigens; among these were monoclonal
antibodiesalso capable of immobilizing virulent T. palli-
0
20
25
35
8
treponemal and rabbit host testicular tissue antigens and
thus washighly cross reactive with all antigens tested in
the RIA.
Table 1 presents an example of the RIA protocol used
to screen anti-T. pallidum hybrids. The data shown are
from one of several typical RIA tests performed, and
represent results characteristic of the majority of clones
producing monoclonal antibodies specifically against T.
pallidum. Monoclonal antibodies from such clones as
those described in Table 1 did not react well with intact
treponemes. However, they appeared to bind preferen-
tially to sonicated antigens of T. pallidum, suggesting
that they may be directed against either intracellular or
“masked” antigens. Their specificity for T. pallidum
determinants was indicated by their failure to cross
react with T. phagedenis biotype Reiter antigen prepara-
tions and with rabbit testicular tissue antigens. These
monoclonal antibodies were of mouse classes IgG and
IgM, and were not reactive against 7: pallidum in the
TPI test. The polyclonal antisera preparations (mouse
anti-T. pallidum and mouse anti-rabbit testicular tissue)
used as positive controls in the RIA werestrongly posi-
tive against all antigens tested. This was expected be-
cause the mouse anti-T. pallidum antibodies were de-
rived from mice sensitized with T. pallidum suspensions
containing both treponemal group antigens (that cross
react with antigens of 7. phagedenis biotype Reiter) as
well as contaminating rabbit host antigens. Similarly,
mouseanti-rabbit testicular antibodies also reacted with
treponmal antigens due to the presence of shared anti-
gens common to both rabbit host tissues and trepo-
nemes.
Monoclonal Antibody Isotype Assays
Mouse antibody isotypes were identified by solid
phase RIA. Cooke microtiter plates were coated with
goat anti-mouse immunoglobulin. Culture supernatants
were then added and incubated for 3 hr at 37° C. Iodi-
nated, affinity purified rabbit anti-mouse heavy chain
specific reagents were addedto identify the isotype ofdum organisms in the Treponema Pallidum Immobiliza- 40 antibody boundtotheplate.
TABLE1
Radioimmunoassay (!25] counts/0.4 min) on five representative hybridomacell lines
producing monocional antibodies against T. pallidum
 
ANTIGENS
Antibody
Clone T. pal! ‘T. pal-aged2 TT. pal-son>? Reiter Reiter-son5 Rabbit® Isotype
9B12 175 429 2,594 173 200 118 IgGl
6F6 280 243 2,455 206 219 233 IgM
13D4 187 274 2,220 207 195 200 IgGi
12D10 270 215 2,013 195 138 153 IgG2a
7E3 226 189 1,742 207 192 195 IgG3
Control Antisera:
PBS 229 220 298 252 175 214
DMEM Medium 201 194 167 189 225 183
Mouseanti- 20,049 20,691 21,274 18,433 12,399 11,424
T. pal’.
Mouseanti- 18,314 17,973 19,872 15,826 13,646 18,799rabbit8
 "ntactfreshly isolated 7. pallidum
Intact, “aged” T. pallidum
3Sonicate ofT. pallidum
*intact T. phagedenis biotype Rieter
5Sonicate ofT. Phagedenis biotype Rieter
Rabbit testicular extract
71:10 dilutions of mouse anti-T. pallidum serum from sensitized mice
41:10 dilution of mouse anti-rabbit testicular tissue extract serum.
tion test. Another group of monoclonal antibodies re-
acted with both T. pallidum and T. phagedenis biotype 65
Reiter antigens and therefore was apparently directed
against treponemal group antigens. A third group of
monoclonal antibodies was capable of binding both
Four hybridomacell lines secreting antibodiesspecif-
ically against T. pallidum were also isolated that ap-
peared to produce monoclonal antibodies with greater
affinity for possible surface determinants of T. pallidum
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(see Table 2). Monoclonal antibodies from these clonespossessed relatively high reactivity with both intact“aged” treponemesand sonicates of T. pallidum, but notwith freshly isolated treponemes, with one possibleexception, clone 7D7. Little or no cross reactivity withother treponemal or rabbit antigens was observed forthese monoclonal antibodies. Despite their apparentincreased specificity for possible surface componentsofT. pallidum, these monoclonal antibodies were also
nonreactive in the TPItest.
Table 3 shows RIA data demonstrating anti-T. palli-dum hybridomacell lines producing monoclonal anti-bodies capable of reacting against T. pallidum in theTPItest. These clones secreted antibodies of the mouseisotypes which can fix complement. The antibodies didnot react very well, however, with either freshly iso-lated intact or “aged” intact treponemes. This observa-tion was surprising in view of the reactive TPItest data.
10
TABLE 2
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Because of the multitude of antigenic similaritiesknown to exist between members of the genus Trepo-nemait was not unexpected to generate hybridoma celllines producing monoclonal antibodies that cross re-acted with both 7. pallidum and T. phagedenis biotypeReiter antigenic determinants. However, only 3 of 39anti-T. pallidum hybridomas isolated possessed thischaracteristic (Table 4).
A class of hybridomacell lines was also isolated thatproduced monoclonal antibodies found to cross reactwith all treponemal and rabbit testicular antigens em-ployed in the RIA (Table 5). Because of the limitingdilution procedure employed and thefact that only oneantibody isotype was observed for each cell line (exceptone clone 12H4),it is unlikely that these hybridomacelllines represent more than one hybridomaclone growingtogether in culture. It may be ofinterest to note thatallof these highly cross reactive antibodies were of theIgM class of antibody.
 Radioimmunoassay Results on anti-T7. pallidum hybridomas producing
monocional antibodies against “aged”, intact treponemes.
ANTIGENS!
AntibodyClone T. pal T. pal-aged TT. pal-son’ Reiter Reiter-son Rabbit Isotype
NES + + _ _ - IgG2a8G2 _ + + _ - _ IgG15C9 _ + + _ - _ IgMTD7 + + + _ - - IgM
‘Abbreviations and controls as in Table1.
TABLE3
 Radioimmunoassay Results on anti-7: pallidum hybridomas secretingmonoclonal antibodies reactive in the TPItest.
 
 
ANTIGENS!
AntibodyClone T. pal T. pal-aged TT. pal-son Reiter Reiter-son Rabbit Isotype
3G5 + - + - - _ IgM1306 = +,- + - - - IgG2a5AT7 - - + - - - IgM13G10 - - + _ - - IgG2a4H7 _ _ + - - ~ IgG2b13C8 - - + - _ - IgG2b
‘Abbreviations and controls as in Table 1.
TABLE 4
Rabioimmunoassay (Results) on anti-7: pallidum hybridomas
secreting monoclonal antibodies that cross react with T.
phagedenis biotype Reiter.
ANTIGENS!
AntibodyClone 7. pal T. pal-aged fT. pal-son Reiter Reiter-son Rabbit Isotype
13A7 _ - + + + _ IgM1BI1 - _ + + _ - IgM122G11 - _ + + + - IgG2b
‘Abbreviations and controls as in Table 1.
TABLE5
 Rabioimmunoassay Results on hybridomas secreting monoclonal antibodies thatbind 7. pallidum, T. phagedenis biotype Reiter, and rabbit testicular antigens.
ANTIGENS!
AntibodyClone 7. pal T. pal-aged [. pal-son Reiter Reiter-son Rabbit Isotype
1Cl1 + + + + + + IgM12F4 + + + + + + IgM1870-5A5 + + + + + + IgM6A9 + + + + + + IgM
4,514,49811
TABLE5-continued
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Rabioimmunoassay Results on hybridomas secreting monoclonal antibodies that
bind T. pallidum, T. phagedenis biotype Reiter, and rabbit testicular antigens.
ANTIGENS!
Antibody
Clone fT. pal T. pal-aged T. pal-son Reiter Reiter-son Rabbit Isotype
12E3 - + + +,- + + IgM
‘Abbreviations and controls as in Table 1.
Monoclonal Antibodies in the Treponema pallidum Im-
mobilization (TPI) Test.
Mouseanti-T: pallidum serum, mouse anti-rabbit tes-
ticular extract serum, and monoclonal antibodies se-
creted by anti-T. pallidum hybridomas weretested for
their ability to immobilize virulent T. pallidum (Nich-
ols) in the Treponema pallidum immobilization (TPI)
test. The TPI assay wascarried out, with minor modifi-
cations, as described in the Manual of Tests for Syphilis
(Center for Disease Control, 1964, Dept. of Health,
Education and Welfare, Public Health Service,
N.C.D.C., Atlanta, Ga.). Penicillinase was incorporated
in the test procedure dueto the presence of penicillin in
the hybridoma clone supernatants. Because T. pallidum
wasnotsensitive to streptomycin at the concentrations
employed in the medium, removalofstreptomycin from
the hybridoma clone supernatants was unnecessary.
The following hybridomas exhibited both T. pallidum
specificity and TPI-reactivity:
 
CLONE ANTIBODY ISOTYPE
3G5 IgM
4H7 IgG2b
SA7 IgM
13C6 IgG2a
13C8 IgG2b
13G10 IgG2a
Microhemagglutination (MHA-TP) Test for Treponema
Pallidum Antibodies
The MHA-TPtest (Sera-Tek Treponemal Antibody
Test, Ames Division, Miles Laboratories, Inc.) was
performed as described by the manufacturers. Briefly,3
pl of each fourday old hybridoma clone supernatant
(DMEM medium) containing anti-T. pallidum mono-
clonal antibodies were mixed with 57 pl of absorbing
diluent (1:20 dilution) and allowed to incubate at room
temperature for 30 minutes. For each monoclonal anti-
body preparation, 25 yl aliquots of the absorbed mono-
clonal antibody mixture were then added in duplicate
wells of a 96 well microtiter plate. For each clone sam-
ple, 75 wl of sensitized sheep erythrocytes were added
to one set of wells and 75 jzl of unsensitized sheep eryth-
rocytes were added to the other duplicate wells as a
negative control.
Reactive clones were 8G2 and 11E3; all other hy-
bridoma clone supernatants tested were non-reactive.
It appeared that a greater degree of anti-T. pallidum
specificity was exhibited by IgG secreting clones as
opposed to those clones secreting IgM. Table 6 sum-
marizes the isotypes of all murine anti-T. pallidum
monoclonal antibodies, their specificities, and their fre-
quencyofisolation in this study. A majority (24 of 31
clones) of the hybridomas isolated that reacted only
against T. pallidum antigens were of IgG subclasses,
compared to 7 IgM clones with similar properties. Of 8
total clones that cross reacted with either T. phagedenis
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biotype Reiter or rabbit testicular antigens, 7 of these
were IgM producers.
TABLE6
 
 
Summary of monoclonal antibody characteristics
from 39 anti-T. pallidum hybridomas.Antibody Specificities()
Mouse T. pal +
Antibody Reiter +
Isotype T. pal T. pal + Reiter Rabbit Total
IgM 72) 2 5 141gG3 2 0 0 2IgGl n@ 0 0 11IgG2b 32) 1 0 4
IgG2a 702),(4) 0 0 7IgGlIgG2b@) 1 0 ) 1
Total 31 3 5 39
(abbreviations as in Table 1.
@}Twoof these clones were reactive in the TPItest.@Clone 1939-12H4 (double producer)
One of these clones was reactive in the MHA-TPtest but unreactive in the TPI
test.
A deposit of hybrid cell lines identified herein as 3G5
(TPl-reactive) and 8G2 (MHA-TP-reactive) are on
deposit with the American Type Culture Collection and
assigned the ATCC numbers HB8133 and HB8134,
respectively.
F. Utility
The hybridoma cell lines and the monoclonal anti-
bodies produced therefrom described in this application
are useful in the purification and characterization of the
specific antigenic and immunogenic components pres-
ented by Treponemabacteria and in particular Trepo-
nema pallidum. Moreover, the monoclonal antibodies
produced from a given hybridoma line are homogene-
ous in antigenic recognition and thereby are useful for
subsequent affinity chromatography-based purification
of Treponemaantigens.
The anti-7. pallidum monoclonal antibodies can po-
tentially be used in one or more of many ways for the
development of a new diagnostic test. Various ap-
proaches canbeutilized including both direct and indi-
rect immunoassays. Variations on the general immuno-
assay theme include radioimmunoassay(direct or indi-
rect), fluorescent antibody techniques (direct or indi-
rect), enzyme-linked immunosorbent assays (ELISA’s),
inhibition of hemolysis assays, inhibition of agglutina-
tion tests, agglutination reactions (antibodyligand medi-
ated), and/or complement consumption tests. The use
of one or more anti-T7. pallidum monoclonal antibodies
in such systems would potentially constitute an impor-
tant new and useful test for the diagnosis of early pri-
mary syphilis, by virtue of the fact that the monoclonal
antibodies are specific for 7. pallidum and can be em-
ployed in very sensitive types of immunoassays. Such
sensitive assays may be useful in the diagnosis of con-
genital syphilis or neurosyphilis through the detection
of T. pallidum cells or antigens in congenital syphilitic
lesions or in the cerebrospinal fluid of neurosyphilitics.
4,514,49813
Moreover, the monoclonal antibodies potentiallyprovide new affinity purification réagents that can beused to isolate and purify 7: pallidum cells from rabbittissue, which is curtently performed by very expensiveandinefficient methods. Throughthe use ofmonoclonal
antibodyaffinity column chromatography,affinity puri-fied T. pallidum cells can be prepared and employed asdiagnostic antigen in currently existing serodiagnostic
tests for syphilis. Such affinity purified treponemalcellsmay also increase thesensitivity of the pre-existing testssince this material will be much “cleaner” than conven-tionally prepared T. pallidum cells (i.c., free of contami-
nating rabbit tissue debris). Also, in lieu of whole T.pallidum cells as an antigen in serodiagnostic tests, themonoclonal antibodies maypossess theability to affinitypurify newly-defined antigen components of 7. palli-dum cells that can be used in place of whole treponemal
cells as test antigen. Consequently, the monoclonal
antibodies have the ultimate potential of both identify-ing new antigenic components of the organism as well
as the ability to purify them out from fractionated T.pallidum cells.
Ultimately, the affinity purified 7. pallidum antigen
components may be.used to develop a vaccine for syph-ilis. Although only targeted segments ofthe U.S. popu-
lation would mostlikely be candidates for such a vac-
cine (i.e., gay populations, migrant workers, inner citydwellers, etc.), there are other important treponemal
diseases against which such a vaccine might be effec-
tive. Briefly, the treponemes that cause yaws, pinta, and
bejel are treponemes that are morphologically and sero-logically indistinguishable from T. pallidum. Because ofthe immunological similarities of the yaws, pinta, andbejel organisms to T: pallidum, a vaccine developed
against syphilis may be just as effective against theseendemic treponemal diseases. Thus, the ability to pre-pare affinity purified antigens (immunogens) ofT. palli-dum that are immunogenic may have a very broadapplication to treponemal disease vaccines in general.The foregoing description of the invention has beendirected to particular embodiments for purposes ofexplanation and illustration. It will be apparent, how-ever, to thoseskilled in the art that many modifications
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14 ;
and changes in the processes ofpreparing and imple-menting the described embodiments may be made with-out departing from the essence of the invention. It isapplicants’ intention in the following claims to coverallequivalent modifications and variations as fall within
the scope of the invention.
Whatis claimedis:
1. A composition of matter consisting essentially ofacontinuous murinehybrid cell line that produces mono-clonal antibody against an antigenic determinant ofTreponemapallidum, which cell line-is formed as a fu-sion between a murine myelomacell and a differenti-ated murine lymphoidcell immunized with Treponemapallidum antigen.
2. The composition ofclaim 1 wherein the continuoushybrid cell line is together with a culture medium suit-
able for supporting growth ofthe cell line.
3. The composition of claim 1 wherein the myelomacell is a hybridoma cell or plasmacytomacell.4. The composition of claim 1 wherein the differenti-ated lymphoid cell is an immunespleen cell or lymphnodecell.
5. The composition of claim 1 wherein the continuous
hybrid cell line is a celled hybrid of a BALB/c mouseimmunespleen cell immunized against Treponema pailli-dum antigens, fused to a SP2/0 hyridomacell.6. The composition of claim 1 wherein the hybrid cellline consists essentially of hybridoma clone indentified
as ATCC deposit HB8133 or HB8134.
7. A composition of matter consisting essentially ofmonoclonal antibodies directed against an antigenicdeterminant of Treponema pallidum, said antibodies
produced from a continueus murine hybrid cell lineformed by fusing a murine myelomacell with a differen-tiated murine lumphoid cell immunized against Trepo-
nema pallidum antigens.
8. The composition of claim 7 wherein the mono-clonal antibodies are capable offixing complement and
immobilizing virulent Treponema pallidum organisms.
9. The composition of claim 7 wherein the mono-
clonal antibodies are produced by the hybrid cell lines
identified as ATCC deposit HB8133 or HB8134.
* ** * *
